Pyruvate dehydrogenase kinase as a novel therapeutic target ... | 食品添加物合法業者資訊網

由GSutendra著作·2013·被引用236次—InhibitionofPDKwitheithersmallinterferingRNAsortheorphandrugdichloroacetate(DCA)shiftsthemetabolismofcancercellsfrom ...

Traditional drug development in oncology has focused on pathways that are essential for the survival of all cells. The major limitation of this approach is the selectivity of treatment to cancer cells. Alternatively, selectivity to cancer cells can be achieved by targeting non-essential pathways that are only critical for the survival of cancer cells, but this approach has limited efficacy. Overall, it is difficult to target both selective and essential pathways in current oncology, although there are exceptions. For example, chronic myelogenous leukemia (CML) cells dependence on BCR-ABL tyrosine kinase is induced by a chromosomal translocation only in the malignant cells (Rowley, 1973[1]), making Gleevec a selective and effective treatment for CML (Kamb et al., 2007[2]). Similarly, herceptin, an antibody that inhibits human epidermal growth factor receptor 2 (HER2) on HER2-positive breast cancers (Eisenhauer, 2001[3]; Slamon et al., 2001[4]) is also selec...